Cancer could be deemed as an abnormal and uncontrolled tissue repair process. Therefore, it would not be surprising that factors that function in the tissue repair process, such as cytokines, chemokines, growth factors and Toll-like receptor (TLR) ligands, as well as growth signals for compensatory proliferation, would also be key factors in regulating and enhancing cancer progression. The TLR pathways, which play a critical role in tissue repair, are also key regulators in cancer progression as well as chemoresistance. TLRs serve as cell surface sensors that can initiate pathways leading to proliferation and chemoresistance; as well as mediators that are able to regulate the infiltrating immune cells to provide further support for cancer progression.
Your institute does not have access to this article
Open Access articles citing this article.
Virchows Archiv Open Access 19 May 2020
Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer
Scientific Reports Open Access 15 August 2018
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling
Journal of Ovarian Research Open Access 17 January 2018
Subscribe to Journal
Get full journal access for 1 year
only $2.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Akira S, Yamamoto M, Takeda K . (2003). Role of adapters in Toll-like receptor signalling. Biochem Soc Trans 31: 637–642.
Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W et al. (2006). Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 106: 599–608.
Balkwill F, Coussens LM . (2004). Cancer: an inflammatory link. Nature 431: 405–406.
Balkwill F, Mantovani A . (2001). Inflammation and cancer: back to Virchow? Lancet 357: 539–545.
Barton GM, Medzhitov R . (2004). Toll signaling: RIPping off the TNF pathway. Nat Immunol 5: 472–474.
Beachy PA, Karhadkar SS, Berman DM . (2004). Mending and malignancy. Nature 431: 402.
Ben-Hur H, Gurevich P, Ben-Arie A, Huszar M, Berman V, Tendler Y et al. (2000a). Apoptosis and apoptosis-related proteins (Fas, Fas ligand, bcl-2, p53) in macrophages of human ovarian epithelial tumors. Eur J Gynaecol Oncol 21: 141–145.
Ben-Hur H, Gurevich P, Huszar M, Ben-Arie A, Berman V, Tendler Y et al. (2000b). Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors. Eur J Gynaecol Oncol 21: 53–57.
Burns K, Martinon F, Esslinger C, Pahl H, Schneider P, Bodmer JL et al. (1998). MyD88, an adapter protein involved in interleukin-1 signaling. J Biol Chem 273: 12203–12209.
Calin GA, Croce CM . (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857–866.
Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL . (2007a). Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13: 851–856.
Chen R, Alvero AB, Silasi D-A, Kelly M, Fest S, Leiser A et al. (2007b). Molecular typing of epithelial ovarian cancer: implications on chemoresponse and tumor progression. J Clin Invest (Submitted).
Chen R, Alvero AB, Silasi D-A, Mor G . (2007c). Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 57: 93–107.
Coussens LM, Werb Z . (2002). Inflammation and cancer. Nature 420: 860–867.
Covert MW, Leung TH, Gaston JE, Baltimore D . (2005). Achieving stability of lipopolysaccharide-induced NF-kappaB activation. Science 309: 1854–1857.
Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF et al. (2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102: 3627–3632.
Ernst PB, Takaishi H, Crowe SE . (2001). Helicobacter pylori infection as a model for gastrointestinal immunity and chronic inflammatory diseases. Dig Dis 19: 104–111.
Esquela-Kerscher A, Slack FJ . (2006). Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.
Fukata M, Michelsen KS, Eri R, Thomas LS, Hu B, Lukasek K et al. (2005). Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288: G1055–G1065.
Gannot G, Gannot I, Vered H, Buchner A, Keisari Y . (2002). Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer 86: 1444–1448.
Girling JE, Hedger MP . (2007). Toll-like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology. Immunol Cell Biol 85: 481–489.
Giudice LC, Kao LC . (2004). Endometriosis. Lancet 364: 1789–1799.
Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X et al. (2005). Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 174: 1259–1268.
Gupta RA, Dubois RN . (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11–21.
Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C et al. (2002). Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101: 415–422.
He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. (2005). The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075–19080.
He W, Liu Q, Wang L, Chen W, Li N, Cao X . (2007). TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44: 2850–2859.
Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526–1529.
Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH et al. (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65: 5009–5014.
Huang B, Zhao J, Shen S, Li H, He KL, Shen GX et al. (2007). Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 67: 4346–4352.
Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. (2005). Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173–1179.
Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M et al. (2003). Phenoxodiol—an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 22: 2611–2620.
Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. (2006). TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859–3868.
Koff JL, Shao MX, Kim S, Ueki IF, Nadel JA . (2006). Pseudomonas lipopolysaccharide accelerates wound repair via activation of a novel epithelial cell signaling cascade. J Immunol 177: 8693–8700.
Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O et al. (2004). NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol 166: 369–380.
Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A . (2002). Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603–607.
Lewis CE, Pollard JW . (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605–612.
Li Q, Withoff S, Verma IM . (2005). Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 26: 318–325.
Lin WW, Karin M . (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175–1183.
Lotze MT, Tracey KJ . (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331–342.
McDermott EP, O'Neill LA . (2002). Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. J Biol Chem 277: 7808–7815.
Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N et al. (1997). Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3: 817–819.
Mor G, Straszewski S, Kamsteeg M . (2002). Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. Biochem Pharmacol 64: 1305–1315.
Mor G, Yue W, Santen RJ, Gutierrez L, Eliza M, Berstein LM et al. (1998). Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 67: 403–411.
Muzio M, Ni J, Feng P, Dixit VM . (1997). IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278: 1612–1615.
Nakanishi C, Toi M . (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297–309.
O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D . (2007). MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA 104: 1604–1609.
Philip M, Rowley DA, Schreiber H . (2004). Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 14: 433–439.
Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ . (1999). The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 81: 1311–1317.
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S et al. (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461–466.
Pollard JW . (2004). Tumor-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71–78.
Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW . (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23: 2934–2949.
Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS . (2005). Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA 102: 99–104.
Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R . (2004). Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118: 229–241.
Rana TM . (2007). Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8: 23–36.
Riman T, Nilsson S, Persson IR . (2004). Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83: 783–795.
Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF . (1998). A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 95: 588–593.
Ruvkun G . (2001). Molecular biology. Glimpses of a tiny RNA world. Science 294: 797–799.
Sato S, Sugiyama M, Yamamoto M, Watanabe Y, Kawai T, Takeda K et al. (2003). Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 171: 4304–4310.
Schwartz PE . (2002). Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 107: 99–118.
Sekizawa A, Amemiya S, Otsuka J, Saito H, Farina A, Okai T et al. (2004). Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes. Med Electron Microsc 37: 97–100.
Shishodia S, Aggarwal BB . (2002). Nuclear factor-kappaB activation: a question of life or death. J Biochem Mol Biol 35: 28–40.
Silasi D-A, Alvero AB, Illuzzi J, Kelly MG, Chen R, Fu H-H et al. (2006). MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med 79: 153–163.
Taganov KD, Boldin MP, Chang KJ, Baltimore D . (2006). NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103: 12481–12486.
Takeda K, Akira S . (2004). TLR signaling pathways. Semin Immunol 16: 3–9.
Takeda K, Kaisho T, Akira S . (2003). Toll-like receptors. Annu Rev Immunol 21: 335–376.
Tam W, Ben-Yehuda D, Hayward WS . (1997). bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol 17: 1490–1502.
Tsan MF . (2006). Toll-like receptors, inflammation and cancer. Semin Cancer Biol 16: 32–37.
Virchow R . (1858). Reizung und Reizbarkeit. Arch Pathol Anat Klin Med 14: 1–63.
Virchow R . (1863). Die Krankhaften Geschwulste. Verlag von August Hirschwald: Berlin, pp 57–101.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257–2261.
Werner SL, Barken D, Hoffmann A . (2005). Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309: 1857–1861.
Wesche H, Henzel WJ, Shillinglaw W, Li S, Cao Z . (1997). MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7: 837–847.
Wiemer EA . (2007). The role of microRNAs in cancer: no small matter. Eur J Cancer 43: 1529–1544.
Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS et al. (2005). TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308: 1626–1629.
Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA et al. (2004). A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522–1526.
About this article
Cite this article
Chen, R., Alvero, A., Silasi, DA. et al. Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. Oncogene 27, 225–233 (2008). https://doi.org/10.1038/sj.onc.1210907
- ovarian cancer
- Toll-like receptors
- tissue repair
Nature Reviews Cancer (2022)
CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential
Virchows Archiv (2020)
Medical Oncology (2019)
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling
Journal of Ovarian Research (2018)